Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- AnGes Calls off Japan Development of Collategene for Additional Indication
September 8, 2022
- AnGes Jettisons Ancestral COVID-19 Vaccine Program
September 8, 2022
- Promotions via In-Hospital Seminars, Webinars Record Two-Digit Rise YOY in July: Intage
September 7, 2022
- Sysmex Files Gene Profiling Test as CDx for Taiho’s Futibatinib
September 7, 2022
- Opdivo Best-Selling Drug in Japan for 8 Months on End: Encise
September 7, 2022
- Pfizer Japan to Stop Amoxapine Shipments, Start Recall in February after Carcinogen Detection
September 7, 2022
- Tatsumi Kagaku Likely to Halt Shipments of 46 Products after Administrative Penalty
September 6, 2022
- Moderna to File BA.4/5-Targeting Booster Jab in Japan
September 6, 2022
- Teijin Gets Approval for 14-Day Version of Osteoporosis Med Ostabalo
September 6, 2022
- Leo Pharma Japan Names Finance Head Kook Hyun Son as Interim Chief
September 2, 2022
- Nitrosamine Impurity Detected in Sitagliptin, Shipments in Japan to Continue with FDA-Set Limit: MSD/Ono
September 2, 2022
- CureApp’s Hypertension Therapeutic App Rolls Out with Insurance Coverage
September 2, 2022
- AstraZeneca Japan Sets Up New Biz Unit for Vaccines and Immune Therapies
September 2, 2022
- Daiichi Sankyo Begins PIII Primary Dose Study for mRNA COVID Jab
September 2, 2022
- Pfizer Discussing Filing of BA.5-Based Vaccine with Japanese Authorities
September 1, 2022
- Servier to Bolster Japan Business with Focus on Oncology: President Laureau
September 1, 2022
- Pfizer Japan to Curb Shipments and Recall Amoxapine over Carcinogen Risks
September 1, 2022
- Nobelpharma Makes Global Debut with US Launch of Hyftor
September 1, 2022
- BMS, Nagoya University Tie Up for Innovative Drug Discovery
August 31, 2022
- Eisai Files New Injection Formulation of Fycompa in Japan
August 31, 2022
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…